EDT Cathie Wood’s ARK Investment buys 135K shares of Beam Therapeutics (BEAM) todayStay Ahead of the Market: Discover outperforming ...

Beam Therapeutics Inc. (BEAM) shares ended the last trading session 12.6% higher at $16.37. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...

Beam Therapeutics Inc. (NASDAQ:BEAM) on Saturday presented additional data from the Phase 1/2 clinical trial of BEAM-302 in ...

Scotiabank analyst Greg Harrison maintained a Buy rating on Beam Therapeutics (BEAM – Research Report) today and set a price target of $40.00.

KLP Kapitalforvaltning AS purchased a new stake in shares of Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) in the fourth ...

Mitsubishi UFJ Asset Management Co. Ltd. lowered its position in Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) by 9.4% ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Fintel reports that on March 28, 2025, B of A Securities upgraded their outlook for Beam Therapeutics (NasdaqGS:BEAM) from Neutral to Buy. Analyst Price Forecast Suggests 125.89% Upside As of ...

Beam Therapeutics Inc. BEAM announced that the FDA has cleared the investigational new drug (IND) application to begin clinical studies on its pipeline candidate, BEAM-302, for the treatment of ...

Beam Therapeutics (NASDAQ:BEAM) has been analyzed by 9 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below offers a condensed view ...